Recent clinical trials investigated intranasal NGF delivery in patients with TBI (Phase II, NCT01212679, 2017), or with ischemic stroke (Phase IV, NCT03686163, 2020), but results have not been reported yet. This evidence concerns the gene NGF and ischemic stroke.